CoChat

Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome

Siamashvili, Maka, Davis, Stephen N. · 2021 · Expert Review of Clinical Pharmacology

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer a unique opportunity to simultaneously address various comorbid associated conditions and phenotypic presentations of polycystic ovary syndrome (PCOS) as these agents improve insulin sensitivity, reduce cardiovascular disease (CVD) risk, result in weight loss, and improve nonalcoholic fatty liver disease.Areas covered: The authors describe trials conducted during the last 5 years and provide an update on exenatide and liraglutide use in PCOS women. Information from the studies investigating GLP-1 RAs effects on reducing CVD risk in PCOS is also presented.Expert opinion: Exenatide and liraglutide are good options for the treatment of PCOS when used alone or in combination with metformin. Especially strong consideration should be given to GLP-1 RAs when developing treatment strategies for PCOS women who are overweight or obese, glucose intolerant, have CVD or its attendant risk factors, and/or are seeking treatment for infertility.

Overview

Integrity signals

Registry

Crossref · 10.1080/17512433.2021.1933433

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 11

  1. Williams T, 2016, Am Fam Physician, 94
  2. Hoeger KM, 2020, J Clin Endocrinol Metab, 105
  3. 10.1900/RDS.2014.11.202 · doi:10.1900/rds.2014.11.202
  4. Oliver-Williams C, 2020, Eur J Prev Cardiol
  5. Barber TM, 2021, Clin Endocrinol (Oxf)
  6. Zheng S, 2017, Obes Med, 7
  7. Jensterle M, 2015, Hormones
  8. Lyu X, 2021, Int J Endocrinol [Internet], 1
  9. Lai Y, 2016, Sci Rep, 6
  10. Lim SS, 2019, Cochrane Database Syst Rev, 2019
  11. Je D, 2007, Circulation, 115, 10

Cited by

See all 82

Metadata

Authors
Siamashvili, M., & Davis, S. N.
Affiliations
University of Maryland, Baltimore (US)
Corresponding author
Davis, Stephen N.
Venue
Expert Review of Clinical Pharmacology
Published
2021-05-27
Volume
14
Issue
9
Pages
1081-1089
ISSN
  • 1751-2433 (ISSN-L)
  • 1751-2441
OpenAlex
W3161120012
Cited by
82
References
40
Citations by year
2026: 14 · 2025: 21 · 2024: 17 · 2023: 19 · 2022: 10 · 2021: 1
FWCI
1.94
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
polycystic ovary syndrome, GLP-1 receptor agonists, exenatide, liraglutide, insulin sensitivity, cardiovascular risk, weight loss, non-alcoholic fatty liver disease, metformin combination therapy, obesity, impaired glucose tolerance, infertility
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Metformin, Polycystic Ovary Syndrome, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. https://app.cochat.ai/papers/10.1080/17512433.2021.1933433
The paper
Siamashvili, M., & Davis, S. N. (2021). Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2021.1933433

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.